Confronto
CagriSema vs. Mazdutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
nessun dato
2259884-03-0
Peso molecolare
nessun dato
4790 g/mol
Emivita
nessun dato
132 h
Sequenza
nessun dato
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteMeccanismo d'azione
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
4
Contraddizioni aperte
0
0
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between CagriSema and Mazdutide?
- CagriSema is classified as "Metabolico", while Mazdutide is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Mazdutide?
- The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Mazdutide in Germany and the United States?
- Germania: CagriSema — Non approvato, Mazdutide — Solo ricerca. Stati Uniti: CagriSema — Non approvato, Mazdutide — Solo ricerca. These are factual summaries with source and review date on the individual pages.